Skip to content

Study on the prevention and treatment of Helicobacter pylori infection with probiotics

Study of probiotic bacteria inhibition of helicobacter pylori infection

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053710
Enrollment
Unknown
Registered
2021-11-28
Start date
2021-11-24
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection of Helicobacter pylori

Interventions

Experimental group1:Lactobacillus paracasei
Experimental group2:Lactobacillus fermentum
Experimental group3:Lactobacillus crispatus
Experimental group4:Lactobacillus rhamnosus +HA
Experimental group5:Hyaluronic acid

Sponsors

Jiangnan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with Helicobacter pylori infection within 12 months of enrollment through 14C-urea breath test, rapid urease test or histological examination; 2. Aged 18 to 65 years, half male and half male; 3. The general health status is good, but whether eradication treatment is required according to the judgment of the investigator; 4. The ability to understand the learning requirements and commit to cooperate with the research throughout the experimental period; 5. Willing to provide written informed consent and basic situation questionnaire; 6. No previous anti-pyloric therapy.

Exclusion criteria

Exclusion criteria: 1. History of gastrointestinal surgery (except appendectomy); 2. Allergy to triple antibiotics or any contraindication to eradication therapy; 3. Pregnant or lactating women; 4. Any history of serious diseases (severe cardiovascular, endocrine, liver and kidney dysfunction, etc.) before the eradication of Helicobacter pylori treatment; 5. Patients will also be excluded if they have taken probiotics, antibiotics or investigational products, respectively, in the month prior to inclusion; 6. Mental illness, which may lead to difficulties in cooperation; 7. Patients who lack self-judgment ability; 8. Alcohol or drug abusers; 9. Subjects participating in other clinical trials; 10. For the purpose of the researcher's notice to the researcher; 11. Those who do not meet the research requirements or the researchers believe that they should not participate in the research.

Design outcomes

Primary

MeasureTime frame
14C breath test;Fecal Metagenome;anti-Hp IgG;TNF-a;Serum cytokines;

Secondary

MeasureTime frame
Blood biochemical examination;Blood routine examination;

Countries

China

Contacts

Public ContactZhai Qixiao

School of Food Science and Technology, Jiangnan University

zhaiqixiao@jiangnan.edu.cn+86 15961760920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026